Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idasanutlin +/- Chemo/Venetoclax in Pediatric R/R Leukemias or Solid Tumors
NCT04029688Phase 2Terminated
- Sponsor
- Roche
- Start
- Jan 2020
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label trial of idasanutlin in neuroblastoma, acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and 1 more (6 arms), sponsored by Roche. Primary endpoints: Adverse Events, Dose-Limiting Toxicities and 3 more. Started Jan 2020; status: terminated.
02
Drugs
idasanutlin
03
Conditions
neuroblastomaacute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)Solid tumors
Beyond the preview
Go deeper on NCT04029688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04029688.